JoomFish-Language Selection
|
Abbott Labs spent more than $10 billion on new acquisitions last year, but the company's CEO says his appetite for buyouts has yet to be completely sated. "We're obviously focused on the integration preparation for Solvay when it closes," says CEO Miles White (photo). "I don't in any way think that that consumes our activity so much that we're unprepared for anything else. I wouldn't tell you that we're so busy and at capacity that we can't do anything else." Abbott paid $3 billion for Advanced Medical Optics and $6.6 billion for the prescription drug business of Solvay. But White declined to say what might attract Abbott's interests now, indicating only that the company is very interested in emerging markets. - read the story from the Chicago Tribune Related Articles: |
Adebiotech
ALMA
Alosta
Alsace Biovalley
Amanda Conrad Translations
Actulabo
Hungarian Biotechnology Association
Px therapeutics
Vivactis Advance
Commission Européenne
Agence Nationale de la recherche
HAS
Inserm
Ministère de l'enseignement supérieur et de la recherche
Angels santé
Cerenis therapeutics
CISS
Fovea pharmaceuticals
IMS Health
Janssen Cilag
Paris Biotech Santé
Pharmaceutiques
Px therapeutics
Px therapeutics
Px therapeutics
Px therapeutics
Px therapeutics
Europharm
Px therapeutics
Px therapeutics
Px therapeutics
Px therapeutics
Px therapeutics
Px therapeutics
Px therapeutics
Px therapeutics
Px therapeutics
Px therapeutics
Px therapeutics
Px therapeutics
Px therapeutics
Px therapeutics
Oxo pharma
Px therapeutics
Px therapeutics
Px therapeutics
RWS GROUP
Px therapeutics
Sigma
Px therapeutics
Px therapeutics
Px therapeutics
Px therapeutics
Px therapeutics
Advanstar
Adebiotech
Adebiotech
Adebiotech
Adebiotech
Adebiotech
Adebiotech
Adebiotech
Adebiotech
Adebiotech
Adebiotech
Adebiotech
Adebiotech
Adebiotech
Adebiotech
Adebiotech
Adebiotech
Adebiotech
Adebiotech
PMGROUP
Adebiotech
Adebiotech
Adebiotech
Adebiotech
Adebiotech
STP Pharma
Adebiotech
Adebiotech
Adebiotech
Adebiotech
Adebiotech
Adebiotech
Adebiotech
